Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by grosdavidon Apr 27, 2020 1:38pm

77 Views

Post# 30958417

RE:RE:The profit-takers are here and selling,

Impatient bast@rd....sad to see you leave but I think it best for all of us.

Shaking the tree from the shorts, alot of buyers under 0,45$, intelligent and stronger minded investors are the ones that stay and see the potential over months period of time, not 5 hours trading.

It would be best for you to sell your shares at 0,42$, I will buy them.

Thanks,
David

Bullboard Posts

Sony’s Alpha 1 II: A new professional photography standard?